Blockade of EphA4 signaling ameliorates hippocampal synaptic dysfunctions in mouse models of Alzheimer's disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 27, 2014, Pages 9959-9964

  Fu, Amy K Y ^a   Hung, Kwok Wang ^a   Huang, Huiqian ^a   Gu, Shuo ^a   Shen, Yang ^a   Cheng, Elaine Y L ^a   Ip, Fanny C F ^a   Huang, Xuhui ^a   Fu, Wing Yu ^a   Ip, Nancy Y ^a  

^a HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Abeta; Drug discovery; Ephrin; Receptor tyrosine kinase

Indexed keywords

EPHRIN RECEPTOR A4; RHYNCHOPHYLLINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HIPPOCAMPAL NEURONAL CULTURE; LONG TERM POTENTIATION; MOLECULAR DOCKING; MOUSE; MOUSE MODEL; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ABETA; DRUG DISCOVERY; EPHRIN; RECEPTOR TYROSINE KINASE;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; MICE; MICE, TRANSGENIC; RECEPTOR, EPHA4; SYNAPSES;

EID: 84903978323     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1405803111     Document Type: Article

References (51)

1. Selkoe DJ (2002) Alzheimer's disease is a synaptic failure. Science 298(5594):789-791.
2. Walsh DM, et al. (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416(6880):535-539. (Pubitemid 34288854)
3. Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148(6):1204-1222.
4. Lacor PN, et al. (2004) Synaptic targeting by Alzheimer's-related amyloid β oligomers. J Neurosci 24(45):10191-10200. (Pubitemid 39492046)
5. Koffie RM, et al. (2009) Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci USA 106(10):4012-4017.
6. Shankar GM, et al. (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27(11):2866-2875. (Pubitemid 46438992)
7. Li S, et al. (2009) Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62(6):788-801.
8. Hsieh H, et al. (2006) AMPAR removal underlies Abeta-induced synaptic depression and dendritic spine loss. Neuron 52(5):831-843. (Pubitemid 44828454)
9. Snyder EM, et al. (2005) Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8(8):1051-1058. (Pubitemid 41061516)
10. Mucke L, Selkoe DJ (2012) Neurotoxicity of amyloid β-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med 2(7):a006338.
11. Chen Y, Fu AK, Ip NY (2008) Bidirectional signaling of ErbB and Eph receptors at synapses. Neuron Glia Biol 4(3):211-221.
12. Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133(1):38-52.
13. Dalva MB, et al. (2000) EphB receptors interact with NMDA receptors and regulate excitatory synapse formation. Cell 103(6):945-956.
14. Murai KK, Pasquale EB (2011) Eph receptors and ephrins in neuron-astrocyte communication at synapses. Glia 59(11):1567-1578.
15. Bourgin C, Murai KK, Richter M, Pasquale EB (2007) The EphA4 receptor regulates dendritic spine remodeling by affecting beta1-integrin signaling pathways. J Cell Biol 178(7):1295-1307. (Pubitemid 47480233)
16. Fu WY, et al. (2007) Cdk5 regulates EphA4-mediated dendritic spine retraction through an ephexin1-dependent mechanism. Nat Neurosci 10(1):67-76.
17. Richter M, Murai KK, Bourgin C, Pak DT, Pasquale EB (2007) The EphA4 receptor regulates neuronal morphology through SPAR-mediated inactivation of Rap GTPases. J Neurosci 27(51):14205-14215. (Pubitemid 351377865)
18. Chen Y, Fu AKY, Ip NY (2012) Eph receptors at synapses: Implications in neurodegenerative diseases. Cell Signal 24(3):606-611.
19. Fu AK, et al. (2011) APC(Cdh1) mediates EphA4-dependent downregulation of AMPA receptors in homeostatic plasticity. Nat Neurosci 14(2):181-189.
20. Simón AM, et al. (2009) Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease. J Alzheimers Dis 17(4):773-786.
21. Murai KK, Nguyen LN, Irie F, Yamaguchi Y, Pasquale EB (2003) Control of hippocampal dendritic spine morphology through ephrin-A3/EphA4 signaling. Nat Neurosci 6(2):153-160. (Pubitemid 36182784)
22. Sheng M, Sabatini BL, Südhof TC (2012) Synapses and Alzheimer's disease. Cold Spring Harb Perspect Biol 4(5):a005777.
23. Jacobsen JS, et al. (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 103(13):5161-5166.
24. Klein R (2009) Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat Neurosci 12(1):15-20.
25. Bowden TA, et al. (2009) Structural plasticity of eph receptor A4 facilitates cross-class ephrin signaling. Structure 17(10):1386-1397.
26. Murai KK, et al. (2003) Targeting the EphA4 receptor in the nervous system with biologically active peptides. Mol Cell Neurosci 24(4):1000-1011. (Pubitemid 38091512)
27. Lacor PN, et al. (2007) Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27(4):796-807. (Pubitemid 46174498)
28. Noberini R, et al. (2008) Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem 283(43):29461-29472.
29. Shankar GM, et al. (2008) Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14(8):837-842.
30. Lambert MP, et al. (1998) Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95(11):6448-6453.
31. Qin H, et al. (2010) Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity. J Biol Chem 285(1):644-654.
32. Singla N, et al. (2010) Crystal structure of the ligand-binding domain of the promiscuous EphA4 receptor reveals two distinct conformations. Biochem Biophys Res Commun 399(4):555-559.
33. Qin H, Shi J, Noberini R, Pasquale EB, Song J (2008) Crystal structure and NMR binding reveal that two small molecule antagonists target the high affinity ephrin-binding channel of the EphA4 receptor. J Biol Chem 283(43):29473-29484.
34. Zhou J, Zhou S (2010) Antihypertensive and neuroprotective activities of rhynchophylline: The role of rhynchophylline in neurotransmission and ion channel activity. J Ethnopharmacol 132(1):15-27.
35. Cissé M, et al. (2011) Reversing EphB2 depletion rescues cognitive functions in Alzheimer model. Nature 469(7328):47-52.
36. Shen L, et al. (2010) Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage 53(3):1051-1063.
37. Logue MW, et al. (2011) A comprehensive genetic association study of Alzheimer disease in African Americans. Arch Neurol 68(12):1569-1579.
38. Filosa A, et al. (2009) Neuron-glia communication via EphA4/ephrin-A3 modulates LTP through glial glutamate transport. Nat Neurosci 12(10):1285-1292.
39. Masliah E, et al. (2000) Abnormal glutamate transport function in mutant amyloid precursor protein transgenic mice. Exp Neurol 163(2):381-387. (Pubitemid 30399086)
40. Lamberto I, et al. (2012) Distinctive binding of three antagonistic peptides to the ephrin-binding pocket of the EphA4 receptor. Biochem J 445(1):47-56.
41. Noberini R, et al. (2011) A disalicylic acid-furanyl derivative inhibits ephrin binding to a subset of Eph receptors. Chem Biol Drug Des 78(4):667-678.
42. Kang TH, et al. (2002) Rhynchophylline and isorhynchophylline inhibit NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 455(1):27-34.
43. Kang TH, et al. (2004) Protective effect of rhynchophylline and isorhynchophylline on in vitro ischemia-induced neuronal damage in the hippocampus: Putative neurotransmitter receptors involved in their action. Life Sci 76(3):331-343.
44. Kawakami Z, Ikarashi Y, Kase Y (2011) Isoliquiritigenin is a novel NMDA receptor antagonist in kampo medicine yokukansan. Cell Mol Neurobiol 31(8):1203-1212.
45. Lambert MP, et al. (2001) Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79(3):595-605. (Pubitemid 33029933)
46. Morris GM, et al. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19(14):1639-1662. (Pubitemid 128590223)
47. Huey R, Morris GM, Olson AJ, Goodsell DS (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem 28(6):1145-1152. (Pubitemid 46506716)
48. Bouvier D, et al. (2010) EphA4 is localized in clathrin-coated and synaptic vesicles in adult mouse brain. J Neurochem 113(1):153-165.
49. Sala C, et al. (2003) Inhibition of dendritic spine morphogenesis and synaptic transmission by activity-inducible protein Homer1a. J Neurosci 23(15):6327-6337. (Pubitemid 36875634)
50. Shi L, et al. (2007) Alpha2-chimaerin interacts with EphA4 and regulates EphA4-dependent growth cone collapse. Proc Natl Acad Sci USA 104(41):16347-16352. (Pubitemid 350099407)
51. Shen Y, Fu W-Y, Cheng EYL, Fu AKY, Ip NY (2013) Melanocortin-4 receptor regulates hippocampal synaptic plasticity through a protein kinase A-dependent mechanism. J Neurosci 33(2):464-472.